COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,233 Articles (22,733 medRxiv, 8,500 bioRxiv)

Most recent first Previous |  Page 1111: Articles 11101-11110  | Next

Antiviral activity of molnupiravir precursor NHC against Variants of Concern (VOCs) and its therapeutic window in a human lung cell model
Prince, T., Donovan-Banfield, I., Goldswain, H., Penrice-Randal, R., Turtle, L., Fletcher, T., Khoo, S., Hiscox, J. A.
10.1101/2021.11.23.469695 — Posted: 2021-11-24 Discussion: Onsite
LRRC15 is an inhibitory receptor blocking SARS-CoV-2 spike-mediated entry in trans
Song, J., Chow, R. D., Pena-Hernandez, M., Zhang, L., Loeb, S. A., So, E.-Y., Liang, O. D., Wilen, C. B., Lee, S.
10.1101/2021.11.23.469714 — Posted: 2021-11-24
SARS-CoV-2 Delta Spike Protein Enhances the Viral Fusogenicity and Inflammatory Cytokine Production
Ao, Z., Ouyang, M. J., Olukitibi, T. A., Yao, X.
10.1101/2021.11.23.469765 — Posted: 2021-11-24
Characterization of the immune resistance of SARS-CoV-2 Mu variant and the immunity induced by Mu infection
Uriu, K., Cardenas, P., Munoz, E., Barragan, V., Kosugi, Y., Shirakawa, K., Takaori-Kondo, A., Ecuador-COVID19 Consortium, , The Genotype to Phenotype Japan (G2P-Japan) Consortium, , Sato, K.
10.1101/2021.11.23.469770 — Posted: 2021-11-24
Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities
Chen, Y., Sun, L., Ullah, I., Beaudoin-Bussieres, G., Anand, S. P., Hederman, A. P., Tolbert, W. D., Sherburn, R., Nguyen, D. N., Marchitto, L., Ding, S., Wu, D., Luo, Y., Gottumukkala, S., Moran, S., Kumar, P., Piszczek, G., Mothes, W., Ackerman, M. E., Finzi, A. E., Uchil, P. D., Gonzalez, F. J., Pazgier, M.
10.1101/2021.11.24.469776 — Posted: 2021-11-24
Unambiguous detection of SARS-CoV-2 subgenomic mRNAs with single cell RNA sequencing
Cohen, P., DeGrace, E. J., Danziger, O., Patel, R., Rosenberg, B. R.
10.1101/2021.11.22.469642 — Posted: 2021-11-24
Single-domain antibodies efficiently neutralize SARS-CoV-2 variants of concern
Favorskaya, I. A., Shcheblyakov, D. V., Esmagambetov, I. B., Dolzhikova, I. V., Alekseeva, I. A., Korobkova, A. I., Voronina, D. V., Ryabova, E. I., Derkaev, A. A., Kovyrshina, A. V., Iliukhina, A. A., Botikov, A. G., Voronina, O. L., Egorova, D. A., Zubkova, O. V., Ryzhova, N. N., Aksenova, E. I., Kunda, M. S., Logunov, D. Y., Naroditsky, B. S., Gintsburg, A. L.
10.1101/2021.11.24.469842 — Posted: 2021-11-24
Distinct SARS-CoV-2 sensing pathways in pDCs driving TLR7-antiviral vs. TLR2-immunopathological responses in COVID-19
van der Sluis, R. M., Cham, L. B., Oliver, A. G., Gammelgaard, K. R., Pedersen, J. G., Idorn, M., Ahmodov, U., Hernandez, S. S., Cemalovic, E., Godsk, S. H., Thyrsted, J., Gunst, J. D., Nielsen, S. D., Jorgensen, J. j., Bjerg, T. W., Laustsen, A., Reinert, L., Olagnier, D., Bak, R. O., Kjolby, M., Holm, C. K., Tolstrup, M., Paludan, S. R., Kristensen, l. S., Sogaard, O. S., Jakobsen, M. R.
10.1101/2021.11.23.469755 — Posted: 2021-11-24
A population framework for predicting the proportion of people infected by the far-field airborne transmission of SARS-CoV-2 indoors
Iddon, C., Jones, B., Sharpe, P., Cevik, M., Fitzgerald, S.
10.1101/2021.11.24.21266807 — Posted: 2021-11-24
Atazanavir is a competitive inhibitor of SARS-CoV-2 Mpro, impairing variants replication in vitro and in vivo
Chaves, O. A., Sacramento, C. Q., Ferreira, A. C., Mattos, M., Fintelman-Rodrigues, N., Temerozo, J. R., Pinto, D. P., da Silveira, G. P. E., da Fonseca, L. B., Pereira, H. M., Carlos, A. S., d'Avila, J. d. C. P., Viola, J. P. B., Monteiro, R. Q., Vazquez, L., Bozza, P. T., Castro-Faria-Neto, H. C., Souza, T. M. L.
10.1101/2021.11.24.469775 — Posted: 2021-11-24

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).